2023 Pitchers

Home » 2023 Pitchers

Start-up Slams

The Award for the most Innovative Start-up goes to:

AgenT-biotech

The Start-up Slams were won by AgenT-biotech, represented by Baptiste Billoir, in the CNS category.

About the project: AgenT is revolutionizing Alzheimer’s care by unlocking the future of precision medicine with our groundbreaking multi-omics blood tests, B-HEALED & B-AHEAD, enabling early and precise detection in pre-dementia stages.

The Merck Award for the most innovative project goes to:

ByoRNA

Merck Group is awarding a special prize to the best start-up working on a biopharmaceutical therapeutic: The Merck Advance Biotech Grant Award.

This prize includes:
• €30,000 to be used towards Merck’s Bioprocessing technologies, Process Development Consultation & Services
• 2 hours of consultation time with M ventures

Congratulations ByoRNA, represented by Pascal Viguié, for winning this Merck Special Prize!

The Start-up Slams showcase young promising companies seeking to raise a seed or a Series A financing round.

Tuesday, December 12^th | 9.00 – 10.30 am

ONCOLOGY

ORAKL ONCOLOGY
Cancer | Techbio | Drug discovery and development

NASASBIOTECH
Glioblastoma | Medical Device | Treatment

CASINVENT PHARMA
Targeted therapy & resistance | Pancreatic cancer Gemcitabine | AML Venetoclax resistance

GLIOCURE
Anti-mitotic peptide | Taxane resistant tumors | TUBB3

REACT THERAPEUTICS
Oncology | Multi-Drug Resistance | New Chemical Entities

ONCOSEMA
Cancer monitoring | Circulating Tumor Cells | Blood test for oncology

DRUG DISCOVERY

URANIA THERAPEUTICS
Genetic disease | Cancer | Small molecule

Tuesday, December 12^th | 2.00 – 3.00 pm

INFLAMMATION

SURVIVX
Sepsis | Immunomodulation | Adjuvant

PHIALOGICS
Autoimmune disease | Biologics | Immune tolerance

NUMA HEALTH
Preventive medicine | Personalized medicine | Bio-analytics

PERIOTRAP PHARMACEUTICALS
Microbiome | Small molecule | Healthcare

Tuesday, December 12^th | 3.15 – 4.30 pm

CNS

AMYL THERAPEUTICS
Neurodegenerative diseases | Amyloidosis | Multi-targets binding

INNOVADE THERAPEUTICS
Depression | Rapid Acting Antidepressant | Synaptic Plasticity

AGENT
Alzheimer’s Disease | Blood Test | Precision Medicine

MEDJEDUSE
Traumatic spinal cord injury | Tissue engineering biomaterial | Sensory-motor recovery

LACTABICO
Peptides | Anxiety disorders | Metabolic disorders

Wednesday, December 13^th | 9.00 – 10.00 am

DRUG DISCOVERY

STH BIOTECH
Bioproduction | Therapeutic cannabis| Metabolic engineering

REFOXY PHARMACEUTICALS
Idiopathic Pulmonary Fibrosis | Ageing-diseases | FOXO3

ORIA BIOSCIENCE
New intracellular targets | Organelles | High Throughput Screening

GENERARE
Synthetic biology | Bioinformatics | Natural products

DIAGNOSTIC

MARX BIOTECHNOLOGY
Health Care | Life Sciences | Diagnostics

Wednesday, December 13^th | 10.30 am – 12.15 pm

CARDIOVASCULAR & METABOLIC DISEASES

EXADEX-INNOV
Chronic metabolic diseases | Obesity | Cell therapy

TECHNOLOGY PLATFORMS

SEABELIFE BIOTECH
First in class small molecule | Cell death inhibitor | Plateform Technology

EVERSYN
Biobetters & Biosimiliars | Glycoengineering | Oligosaccharides

MT-ACT
NCEs | First in class | Cardiovascular

EPHYRA
Sponge RNA | miRNA | Snowflake RNA (sfRNA)

DRUG DELIVERY

NANOREVIV
Drug Delivery Platform | Antibiotics | Bacterial resistances

APILLET
Enteric encapsulation/coating | Nutraceuticals & pharmaceutica | Natural materials

THERALIA
Drug delivery | Personalized medicine | Targeted antibiotics

Wednesday, December 13^th | 2.00 – 3.15 pm

IMMUNOLOGY

BYORNA
RNA | Vaccine| Cancer

LOVALTECH
Nasal vaccines | Universal protein vaccine | Mucosal immunity

IMMUNEWATCH
Immunology | T cells | AI

ONCO-IMMUNOLOGY

MODIBLAST PHARMA
Leukemia | Immunomodulation | Dendritic Cell

ONCOBONE VENTURES
Bone metastasis | Immunotherapy | Preclinical testing

Collaborative and licensing opportunity presentations

The Award for the most Promising Technology goes to:

San Raffaele University and Research Hospital

The most promising technology award went to the San Raffaele University and Research Hospital with their CAR/TCR T Cell Therapy project.

“I was delighted to participate to the Collaborative and Licensing Opportunity pitch session. The session provided a valuable platform to showcase our projects and explore potential collaborations. The engagement and interest from committee members and participants were truly encouraging, and I believe this will pave the way for exciting partnerships in the near future.
I am pleased with the productive outcomes of the BioFIT event, especially the significant number of B2B meetings I attended. These meetings were instrumental in fostering connections, exchanging ideas, and exploring collaborative opportunities. Overall, BioFIT proved to be an invaluable platform for networking and exploring synergies within the industry. I am grateful for the opportunity and optimistic about the potential partnerships that may stem from these interactions.” Marco Catucci, Research Business Developer, Ospedale San Raffaele.

The Collaborative and Licensing Opportunity Presentations showcase early-stage technologies from TTOs, universities, research institutes and companies.

Co-organised by:

They pitched at BioFIT 2023:

Tuesday, December 12^th | 9.00 – 10.30 am

INFECTIOUS DISEASES

NANOREVIV – STAPH-EX
Lipid nano-capsules Platform | Antibiotics | Bacterial Resistance

AATEC MEDICAL – AAT
Inflammation | Respiratory | Inhalation

LILLE UNIVERSITY/ INSERM – CANDIDIASIS DIAGNOSIS
Candidiasis | Diagnosis | Monoclonal antibody

BIOASTER – COLICIN/IMMUNITY TECHNOLOGY
Multiplexing | Immunoassay | Diagnostic

G.ST ANTIVIRALS – 2-DEOXYGLUCOSE TREATMENT
Respiratory viral infections | 2-deoxyglucose | Spray and nebulizer

Tuesday, December 12^th | 5.00 – 6.15 pm

CELL & GENE THERAPY

FONDAZIONE TELETHON ETS – 3D CELL CULTURE
3D cell culture | Gene Therapy | Nichioids

FONDAZIONE TELETHON ETS – CASWITCH
Gene circuit | Biosensor | Inducible gene expressio (no leakiness)

FONDAZIONE TELETHON ETS – IL-1RA GENE THERAPY
Gene Therapy | IL-1RA | Systemic Autoinflammatory Diseases

FONDAZIONE TELETHON ETS – TOLEROGENIC DC TECHNOLOGIES
Tolerogenic Dendritic Cells | Autoimmune diseases | Cell Therapy

CNS

CILCARE – AUDITORY MEASUREMENTS
Auditory | Biomarker | CNS

KVANTIFY – DRUG DISCOVERY TOOL
Drug discovery | CNS | Small molecule

UNIVERSITY OF ANTWERP – INEUROVIR
Viral infection | Neurodegenerative | High throughput screening

IOCB TECH
Neurosteroids | Neuropathic pain | Epilepsy

Wednesday, December 13^th | 9.00 – 10.00 am

ONCOLOGY

ERASMUS MC – CHROMSTRETCH
DNA replication | Replication stress | Cancer

MINOS BIOSCIENCES – SINGLE – CELL ANALYSIS
Oncology / Immuno-oncology | Single-cell functional analysis | Multi-omic analysis

SAN RAFFAELE UNIVERSITY AND RESEARCH HOSPITAL – CAR/TCR T CELL THERAPY
CAR | Adoptive cell therapy | Cancer

UNIVERSITY OF GRENOBLE ALPES (UGA) – TERG
Glioma | Antisense oligonucleotide | Sensitization

AKRIBION GENOMICS – G-DASE E
Programmable anti-cancer drugs | RNA biomarkers | Head & neck cancer

Animal Health Presentations

The Award for the most Innovative Animal Health Project goes to:

the LUCKY project from SATT PARIS SACLAY

Stéphane Gobron, Project Manager in Life Sciences, is the winner of this year’s edition of the Animal Health Presentations, with its project LUCKY from the SATT Paris Saclay.
The project highlights a specific strain of Levilactobacillus brevis, named LBH1073, which exhibits unique anti-proliferative activities and anti-cancer properties.

Exceptionnally this year, the jury decided to award another project with a special jury prize: VETBIOLIX, represented by Matthieu Dubruque, Managing Director.

The Animal Health Presentations focus on innovations in relation to animal well-being and health.

Co-organised by:

They pitched at BioFIT 2023:

Tuesday, December 12^th | 5.00 – 6.00 pm

ANIMAL HEALTH

VETBIOLIX
Cathepsin-K Inhibitor | Adenosin-A3 Agonist | 5-HT4 Agonist

MI:RNA
Blood microRNA | Artificial Intelligence | Early disease diagnosis

VIRCO
Antiviral | Corrol | Poxyvirus / Herpes virus

MYOMU
Sarcopenia | Natural compound | NCE

LUCKY
Probiotic | Anti-proliferative | Pets

Alexandre Breda, Biotech Start-up Manager, Eurasanté
Gary Breit, CEO, Breit Ideas LLP
Vincent Brichard, Venture Partner, EQT Life Sciences
Zuzanna Brzosko, Senior Director, Corporate Strategy & External Innovation, Eli Lilly and Company
Ivan Burkov, Principal, Inkef
Florence Dal Degan, Senior Director, External Innovation, Rare Diseases and Neuroscience, Ipsen
Isabelle Dupin-Roger, Director, R&D External Innovation I Neuroscience and Immuno-inflammation, Servier
Dorothée Gueras Tricart, Head of Biotech division, Eurasanté
Monique Guis, External Innovation Immunology Director, Sanofi
Frank Hensel, Principal, High-Tech Gründerfonds
Dmitrij Hristodorov, Partner, Forbion
Lydia Kalafateli, Venture Developer, NLC Health
Alexandre Laly, Customer Application Consultant – Emerging Biotech, Merck
Esther Lange, Industry Liaison Manager, Ascenion
Marie-Ange N’Zoutani, Head of Acceleration office Sanofi Partnering, Sanofi
Richard Reschen, Associate Director, BD&L Europe, MSD
Olaf Ritzeler, BD&L, Director, Rare Diseases External Innovation / GLOBAL, Sanofi
Corinne Szilagyi, Senior Partner, Biotech Développement Conseils & Member of the Business Development Committee, France Biotech
Kristin Thompson, VP, Chief Business Officer, eureKARE
Joachim Vogt, Director, Search and Evaluation, Western Europe, AbbVie
Ulrich Zugel, Senior Director Emerging Science & Innovation Lead – Inflammation & Immunology Europe, Pfizer
Jean-Christophe Audonnet
Jean-Louis Hunault, President, SIMV
Theo Kanellos, Director Business Development and comercial Alliances, Zoetis
Jean-Pascal Marc, Corporate Product Innovation Director, Virbac
Edouard Timsit, Senior Innovation Scientist, Ceva Santé Animale